January 19, 2012 — Multisite cryoablation of metastatic epithelial ovarian cancer is well tolerated, has a 5-year overall survival rate of 30%, and is cost effective, compared with other forms of ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires ...

IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with ...

Please provide your email address to receive an email when new articles are posted on . Cryoablation may be an effective primary treatment option for women with low-risk breast cancer, according to ...

7-partial-nephrectomy-0516 Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Women with early ...

Cryoablation is a fairly new treatment being used to treat small cancer tumors. Could we soon see it offered as an alternative to traditional breast cancer surgeries? There isn’t a day that goes by ...

A less-invasive treatment technique called hemi-gland cryoablation (HGCryo)—destroying the areas of the prostate where cancers are located by freezing them—provides a high rate of effective prostate ...

NET of the lung: The experience of the Italian registry. Clinical features in surgically treated patients with small cell lung cancer: Risk of brain metastasis and possible role of prophylactic ...

Nephron-sparing surgery for small-to-medium sized renal tumors has undoubtedly become a standard of patient management in the 21 st century. The recent trends toward nephron sparing stem from an ...